Fibrinogen
Fibrinogen is a plasma protein that serves as the final substrate of the coagulation cascade and is also one of the main acute-phase inflammatory proteins — its concentration is assessed both in diagnosing clotting disorders and as an independent cardiovascular risk indicator. This test evaluates clotting function and inflammatory status, distinct from D-dimer, which detects an already-existing clot.
Number of studies
2
Safety
Requires caution
Time to effects
Not applicable — fibrinogen is a diagnostic test, not an intervention.
Who it's for
Table of contents
TL;DR
Fibrinogen is a plasma protein that serves as the final substrate of the coagulation cascade and is also one of the main acute-phase inflammatory proteins — its concentration is assessed both in diagnosing clotting disorders and as an independent cardiovascular risk indicator. This test evaluates clotting function and inflammatory status, distinct from D-dimer, which detects an already-existing clot.
- →Is a key parameter in diagnosing and monitoring disseminated intravascular coagulation (DIC) and other acute coagulopathies
- →Helps explain the cause of unexplained bleeding or, conversely, hypercoagulability, when other clotting tests are ambiguous
- →Supports safety assessment before surgical procedures in patients with suspected hemostatic disorders
| Test type | Fibrinogen concentration in blood plasma, usually via the Clauss method |
|---|---|
| Level of evidence | Moderate — a strongly documented role in hemostasis, a strong observational link to cardiovascular risk, but inconsistent causality |
| Target group | Patients with suspected clotting disorders, in acute hemorrhage or DIC, and in extended cardiovascular risk assessment |
| Key parameters | Fibrinogen concentration (g/L or mg/dL) |
| Preparation | No strict fasting required; avoid significant physical exertion before the test; proper collection into a citrate tube |
| Status | A core test in coagulation medicine and acute states; a supplementary, not first-line, test in cardiovascular risk assessment |
Understand
Overview
Fibrinogen (clotting factor I) is a glycoprotein produced in the liver and circulating in blood at a relatively high concentration, serving as the direct substrate for the final step of the coagulation cascade — under the action of thrombin it's converted into insoluble fibrin, which forms the structural scaffold of a blood clot. The test measures fibrinogen concentration in blood plasma, most often using the Clauss method, and serves a dual diagnostic role: it assesses the blood's ability to clot properly and, independently of that, serves as a marker of inflammatory status and cardiovascular risk.
Fibrinogen's clinical significance stems from its dual biological nature. On one hand, it's an essential component of normal hemostasis — both its deficiency (congenital afibrinogenemia or hypofibrinogenemia, acquired consumptive coagulopathy in DIC or massive hemorrhage) and structural abnormalities (dysfibrinogenemia) can lead to a bleeding disorder. On the other hand, fibrinogen is one of the main acute-phase inflammatory proteins, whose hepatic production rises sharply under the influence of pro-inflammatory cytokines, especially interleukin 6 — for decades, this has led epidemiological studies to link its chronically elevated concentration with a higher risk of atherosclerosis, heart attack, and stroke, independent of classic lipid risk factors.
The test is ordered in several distinct clinical contexts. In diagnosing clotting disorders, fibrinogen is measured as part of a broader coagulation panel for unexplained bleeding, before surgical procedures in patients with suspected bleeding disorders, and above all in monitoring severe emergency conditions — massive obstetric hemorrhage, multi-organ trauma, or disseminated intravascular coagulation (DIC) — where a sharp drop in fibrinogen is one of the key warning signs requiring urgent correction. Independent of this, fibrinogen is sometimes included in an extended cardiovascular risk panel, especially in patients with numerous risk factors where the classic lipid profile doesn't fully explain the observed clinical risk.
Interpreting the result requires knowing the context in which the test was ordered, since the same numbers mean something different in an acute clinical situation than in routine preventive assessment. In acute hemorrhagic states and suspected DIC, what matters is a sharp drop in fibrinogen below a critical value, signaling consumption of clotting factors faster than the liver can replace them. In assessing chronic cardiovascular risk, what matters is a moderate but persistent elevation in concentration, interpreted together with other inflammatory and lipid markers, rather than a single number taken out of context.
Causes of an abnormal result are numerous and differ by direction. Elevated fibrinogen accompanies nearly every inflammatory and infectious state (as an acute-phase reaction), obesity, type 2 diabetes, smoking, pregnancy (physiologically, especially in the third trimester), and chronic inflammatory diseases. Low fibrinogen occurs in severe liver disease (its site of synthesis), in DIC and massive hemorrhage due to consumption, in congenital disorders of fibrinogen synthesis, and transiently after massive fluid transfusions without adequate replacement of clotting factors.
On the practical side, the test doesn't require strict fasting, but it's important to avoid significant physical exertion and to inform the lab of any pregnancy or anticoagulant medications, since these can affect the result or its interpretation. The sample requires proper pre-analytical preparation (a citrate tube, strict adherence to the blood-to-anticoagulant ratio), and collection errors are one of the more common causes of results that don't match the patient's actual clinical state.
Fibrinogen remains a test with dual significance — as a core parameter of hemostatic function in acute states and as an inflammatory marker with an established, though still debated as to causality, role in cardiovascular risk assessment. In clinical practice it's rarely interpreted in isolation — in the acute context it's weighed alongside the full coagulation picture (INR, APTT, platelets), and in the chronic context alongside the lipid profile and other inflammatory markers, since only that comprehensive picture allows a genuine disorder to be distinguished from a transient acute-phase reaction.
Mechanism of action
Fibrinogen is a large, soluble plasma glycoprotein built from two symmetric halves, each consisting of three pairs of polypeptide chains (Aα, Bβ, γ) joined by disulfide bonds. This complex, symmetric structure is essential to its function — it allows the molecule to function as a soluble precursor that, at the right moment in the coagulation cascade, can rapidly polymerize into an insoluble network.
The final step of the coagulation cascade involves thrombin, generated as a result of activation of the extrinsic or intrinsic pathway, enzymatically cleaving short fibrinopeptides A and B from the N-termini of the Aα and Bβ chains of fibrinogen, exposing polymerization sites. The resulting fibrin monomers spontaneously join into elongated protofibrils, which then twist together into thicker fibers, forming a three-dimensional network — the structural scaffold of the clot, additionally stabilized by cross-linking covalent bonds introduced by activated factor XIII.
Independent of its role in hemostasis, fibrinogen is a classic acute-phase protein — its hepatic gene carries elements in its promoter region responsive to interleukin 6, the main pro-inflammatory cytokine released during infection, trauma, or chronic inflammation. In response to elevated IL-6, the liver can increase fibrinogen production several-fold within a few dozen hours, distinguishing it from plasma proteins with constant, low-variability production.
Proposed mechanisms by which chronically elevated fibrinogen would contribute to atherosclerosis and cardiovascular complications include a direct effect on blood viscosity and microcirculatory flow, involvement in platelet aggregation via binding to the platelet receptor GPIIb/IIIa, an effect on the proliferation and migration of vascular smooth muscle cells, and deposition of fibrin in the vessel wall as a component of the atherosclerotic plaque. These mechanisms are biologically plausible, but — as with other inflammatory markers linked to cardiovascular risk — they don't conclusively settle whether fibrinogen is a causal risk factor or merely a reflection of the inflammatory process already underway in the vessel wall.
Fibrinogen's structure as a soluble precursor
The molecule, built from six polypeptide chains, circulates in the blood in soluble form, ready for rapid conversion at the site of vessel injury.
Conversion to fibrin under thrombin's action
Thrombin cleaves fibrinopeptides A and B, exposing polymerization sites and enabling fibrin monomers to form.
Polymerization and stabilization of the fibrin network
Fibrin monomers join into protofibrils and fibers forming the clot's scaffold, further cross-linked by covalent bonds via factor XIII.
Regulation of production as an acute-phase protein
Interleukin 6 drives hepatic transcription of the fibrinogen gene, causing a sharp rise in its concentration in response to inflammation.
Evidence: moderate — based on 2 studies in this database.
Benefits
Common myths
MythFibrinogen and D-dimer are basically the same test.
FactThese are two distinct parameters assessing opposite aspects of clotting — fibrinogen is the substrate from which a clot forms and assesses the blood's ability to clot, while D-dimer is a breakdown product of an already-existing clot and indicates that clotting and subsequent fibrinolysis have already occurred.
MythElevated fibrinogen always means a serious clotting disorder requiring treatment.
FactThe most common cause of moderately elevated fibrinogen is a simple acute-phase reaction accompanying infection, inflammation, or a recent injury, not a primary hemostatic disorder requiring intervention.
MythLowering fibrinogen with supplements or diet always reduces cardiovascular risk the same way treating risk factors pharmacologically does.
FactUnlike, say, LDL cholesterol, there's no solid clinical evidence that deliberately, in isolation, lowering fibrinogen translates into fewer cardiovascular events — its causal role remains a subject of scientific debate.
MythLow fibrinogen is always beneficial because it means lower clotting risk.
FactToo-low fibrinogen concentration, especially in the context of acute bleeding, trauma, or DIC, is a dangerous state that increases bleeding risk, not a favorable deviation from normal.
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
Fibrinogen is the protein from which fibrin is formed under thrombin's action to build a clot — its test assesses the blood's ability to clot. D-dimer is a breakdown product of already-existing, broken-down fibrin, so its presence indicates that clotting and subsequent fibrinolysis has occurred somewhere in the body. These are two different stages of the same process.
Most often it's a reflection of the acute-phase reaction accompanying infection, an inflammatory state, pregnancy, or smoking. Persistently elevated values are sometimes also factored in as an additional element of cardiovascular risk assessment, especially alongside other risk factors.
Yes, it can be dangerous — significantly reduced concentration increases bleeding risk and can signal serious conditions such as disseminated intravascular coagulation, severe liver disease, or massive blood loss, and requires urgent medical evaluation.
Some observational studies link lifestyle factors (quitting smoking, weight loss, regular physical activity) with lower fibrinogen concentration, but there's no solid evidence that deliberately lowering fibrinogen with supplements independently translates into reduced cardiovascular risk.
Mainly in states of acute, massive bleeding, suspected disseminated intravascular coagulation (DIC), after multi-organ trauma, and in obstetric complications, where a sharp drop in fibrinogen requires urgent correction with blood products.
What to combine with
Good combinations
D-dimer — Fibrinogen and D-dimer assess opposite stages of the clotting and fibrinolysis process — they're sometimes ordered together in diagnosing hemostatic disorders and DIC, but don't substitute for each other
CRP and hs-CRP — As acute-phase proteins, fibrinogen and CRP often rise together in inflammatory states, helping distinguish an inflammatory cause from a primary clotting disorder
Lipid Panel — In extended cardiovascular risk assessment, fibrinogen is sometimes interpreted together with the lipid profile as an independent inflammatory-clotting marker
Safety
Side effects & contraindications
Possible side effects
Contraindications
No significant contraindications at typical doses.
Interactions
Any acute inflammatory or infectious state transiently raises fibrinogen as an acute-phase protein, independent of clotting status
Pregnancy, especially in the second and third trimesters, physiologically raises fibrinogen concentration
Oral hormonal contraception and hormone replacement therapy can raise fibrinogen concentration
Smoking and obesity are associated with chronically elevated fibrinogen concentration
Severe liver disease lowers the result due to impaired synthesis of plasma proteins, including fibrinogen
Anticoagulant medications and the course of DIC can significantly lower fibrinogen concentration through its consumption in the clotting process
Is it worth taking?
Who it's for
- Patients with unexplained bleeding or suspected congenital or acquired bleeding disorder
- People in acute, life-threatening states (massive hemorrhage, multi-organ trauma, suspected DIC) where fibrinogen is urgently monitored
- Patients being prepared for surgical procedures with elevated bleeding risk
- People with numerous cardiovascular risk factors for whom a doctor decides to extend risk assessment with inflammatory markers
Not for
- No significant contraindications at typical doses.
Evidence
Worth knowing
Fibrinogen is both a substrate for blood clotting and one of the main acute-phase inflammatory proteins — these two biological functions explain its dual diagnostic significance.
A sharp drop in fibrinogen is one of the key early warning signs of disseminated intravascular coagulation (DIC) in life-threatening states.
A large international individual-participant meta-analysis (Fibrinogen Studies Collaboration) showed a moderately strong association between fibrinogen concentration and the risk of coronary heart disease, stroke, and cardiovascular death.
Physiologically elevated fibrinogen concentration in pregnancy is a natural mechanism preparing the body for childbirth and limiting blood loss.
Studies
People with high plasma fibrinogen concentration have a two to four-fold increased risk of developing cardiovascular disease compared to those with low fibrinogen.
Fibrinogen Studies Collaboration, JAMA, 2005
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis
Strong evidenceFibrinogen Studies Collaboration · JAMA · 2005
An individual-participant meta-analysis of over 150,000 participants from 31 prospective studies, showing a moderately strong association between fibrinogen concentration and the risk of coronary heart disease, stroke, and cardiovascular mortality.
View studyBlood fibrinogen level as a biomarker of adverse outcomes in patients with coronary artery disease: A systematic review and meta-analysis
Moderate evidenceCui Z, Zhao G, Liu X · Medicine (Baltimore) · 2022
A systematic review with meta-analysis of 13 studies covering over 20,000 patients with coronary artery disease, showing significantly higher risk of cardiovascular death and major adverse cardiovascular events with elevated fibrinogen.
View studySources & bibliography
The PubMed identifiers in this knowledge base were checked against NCBI records (October 2026). If you spot an error in a source, please let us know via the contact form.
Compare with similar entries
About the authors of this entry
Author
Redakcja VitMode — Serce i układ krążeniaEditorial team
VitMode Editorial — Heart and Circulation is the VitMode editorial team responsible for: the heart, blood pressure, lipids and cardiovascular prevention. The team has no individual bylines — texts are prepared by VitMode editors from primary sources (clinical trials, meta-analyses, guidelines). Every cited PubMed paper is automatically checked for a matching identifier, title and publication year. The content is educational and does not replace medical advice. Factual errors can be reported in a comment under the post or through the contact form; corrections are made by the editorial team.
75 publications on this site
Editorial review
Redakcja VitMode — Hormony i endokrynologiaEditorial team
VitMode Editorial — Hormones and Endocrinology is the VitMode editorial team responsible for: hormones, testosterone therapy, the thyroid and metabolism. The team has no individual bylines — texts are prepared by VitMode editors from primary sources (clinical trials, meta-analyses, guidelines). Every cited PubMed paper is automatically checked for a matching identifier, title and publication year. The content is educational and does not replace medical advice. Factual errors can be reported in a comment under the post or through the contact form; corrections are made by the editorial team.
328 publications on this site
Related entries
D-dimer
D-dimer is a breakdown product of a blood clot — a test with exceptionally high sensitivity for ruling out deep vein thrombosis and pulmonary embolism, but low specificity, so on its own it almost never confirms a diagnosis.
CRP and hs-CRP
A protein produced by the liver in response to inflammation — in its high-sensitivity form (hs-CRP) it has become one of the most widely studied additional markers of cardiovascular risk.
Lipid Panel
The lipid panel is one of the most important — and still one of the most frequently misread — preventive blood tests: 'total cholesterol' alone tells you less than the ratios between its fractions.
Coagulation Panel — INR, aPTT, and Prothrombin Time (PT)
INR, aPTT, and prothrombin time don't detect the presence of a clot — they measure how efficiently blood can clot at all, evaluating two distinct arms of the coagulation cascade. This is a core panel before surgery, in unexplained bleeding, and for monitoring anticoagulant therapy, and interpreting it requires understanding which pathway each parameter tests.
Complete Blood Count (CBC)
The most commonly ordered laboratory test in the world — a seemingly simple printout hides information about immunity, oxygen transport, and blood clotting, if you know what to look for.
Apolipoprotein B (ApoB)
While a standard lipid panel measures the amount of cholesterol carried in your blood, apolipoprotein B measures something different — the number of particles themselves that can actually penetrate the artery wall. That distinction can matter when a standard lipid panel looks fine but cardiovascular risk remains elevated.
Lipoprotein(a) [Lp(a)]
Unlike LDL or triglycerides, lipoprotein(a) levels are over 80–90% determined by genetics — diet and lifestyle have minimal effect on it. It's the one lipid marker worth testing once in a lifetime, not periodically.
Homocysteine
Homocysteine is an intermediate amino acid of methionine metabolism, linked for decades to cardiovascular and neurological risk — though how much lowering it actually reduces that risk remains a point of controversy in the literature.